prikaz prve stranice dokumenta More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features
  Preuzmi
PDF 1.31 MB
Znanstveni rad - Izvorni znanstveni rad
More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features
Therapeutics and Clinical Risk Management, 17 (2021); 1037-1044. https://doi.org/10.2147/TCRM.S323749
Lucijanić, Marko; Huzjan Korunić, Renata; Sedinic, Martina; Kušec, Rajko; Pejša, Vlatko

Citirajte ovaj rad

Lucijanić, M., Huzjan Korunić, R., Sedinic, M., Kušec, R. i Pejša, V. (2021). More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features. Therapeutics and Clinical Risk Management, 17., 1037-1044. doi: 10.2147/TCRM.S323749

Lucijanić, Marko, et al. "More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features." Therapeutics and Clinical Risk Management, vol. 17, 2021, str. 1037-1044. https://doi.org/10.2147/TCRM.S323749

Lucijanić, Marko, Renata Huzjan Korunić, Martina Sedinic, Rajko Kušec i Vlatko Pejša. "More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features." Therapeutics and Clinical Risk Management 17 (2021): 1037-1044. https://doi.org/10.2147/TCRM.S323749

Lucijanić, M., et al. (2021) 'More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features', Therapeutics and Clinical Risk Management, 17, str. 1037-1044. doi: 10.2147/TCRM.S323749

Lucijanić M, Huzjan Korunić R, Sedinic M, Kušec R, Pejša V. More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features. Therapeutics and Clinical Risk Management [Internet]. 24.09.2021. [pristupljeno 17.01.2025.];17:1037-1044. doi: 10.2147/TCRM.S323749

M. Lucijanić, R. Huzjan Korunić, M. Sedinic, R. Kušec i V. Pejša, "More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features", Therapeutics and Clinical Risk Management, vol. 17, str. 1037-1044, Rujan 2021. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:931158. [Citirano: 17.01.2025.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:931158
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)More Pronounced Muscle Loss During Immunochemotherapy is Associated with Worse Clinical Outcomes in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma with Unfavorable Features
AutorMarko Lucijanić
AutorRenata Huzjan Korunić
AutorMartina Sedinic
AutorRajko Kušec
AutorVlatko Pejša
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Introduction: Cancer-induced cachexia is associated with poor prognosis in patients with non-Hodgkin lymphoma, but it is unknown how and to what extent curable lymphoma treatments affect the musculoskeletal system. ----- Patients and methods: We retrospectively analyzed 104 newly diagnosed diffuse large B-cell lymphoma (DLBCL) patients with unfavorable disease features treated with the R-DA-EPOCH regimen. Psoas muscle area (PMA) measured at L3 vertebra level was compared between staging (pre-therapy) and revision (end of treatment) computerized tomography (CT) scans. ----- Results: Small but significant decline in PMA was observed during the immunochemotherapy period (average loss 5%; P=0.016) with 57.7% of patients experiencing muscle loss. Higher body surface area (OR=17.98 for each m2; P=0.034), number of cycles with dose reduction (OR=2.86 for each cycle; P=0.039) and worse response to therapy (OR=3.09 for each response category; P=0.052) were recognized as independent contributors to the PMA loss in multivariate analysis. One quarter of patients had more pronounced PMA loss (≥21%), which was associated with significantly worse overall and progression-free survival. Both ≥21% PMA loss and non-achieving response to therapy remained independently associated with inferior OS (PMA loss HR=2.98; P=0.016 and achieving response HR=0.04; P<0.001) and PFS (PMA loss HR=3.16; P=0.005 and achieving response HR=0.08; P=0.001) in multivariate analyses. ----- Discussion: Muscle loss occurs in approximately half of newly diagnosed DLBCL patients with unfavorable disease features during R-DA-EPOCH immunochemotherapy. If pronounced, this is associated with worse clinical outcomes irrespectively of achieved response to therapy. Muscle loss seems to be mostly affected by the efficacy and tolerability of the regimen.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaTherapeutics and Clinical Risk Management
Brojčani podacivol. 17, str. 1037-1044
p-ISSN1176-6336
e-ISSN1178-203X
DOIhttps://doi.org/10.2147/TCRM.S323749
URN:NBNurn:nbn:hr:105:931158
Datum objave publikacije2021-09-24
URL dokumentahttps://www.dovepress.com/more-pronounced-muscle-loss-during-immunochemotherapy-is-associated-wi-peer-reviewed-fulltext-article-TCRM
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno 3.0 (CC BY-NC 3.0)
Datum i vrijeme pohrane2022-04-07 11:21:18